Wednesday, April 20, 2016

Second Genome Scoops Up $42.6M

South San Francisco-based Second Genome, which is developing biopharmaceuticals that are aimed at indications associated with barrier function, insulin sensitivity, and immune regulation, has raised $42.6M in a Series B funding. The funding was led by Pfizer Venture Investments and Roche Venture Fund, and also included Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, Mayo Clinic, plus Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, Ph.D. The copany hsa now raised $59M in total.